Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV
Journal of acquired immune deficiency syndromes (1999), v 90(4), pp 377-381
12 Apr 2022
PMID: 35413022
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial are presented here.
REPRIEVE is an atherosclerotic cardiovascular disease (ASCVD) prevention trial among 7,770 PWH on antiretroviral therapy (ART). Beginning April 2020, targeted data on COVID-19 diagnosis and symptoms were collected during routine trial visits. SARS-CoV-2 infection was defined as either COVID-19 clinical diagnosis or presence of SARS-CoV-2 IgG or IgA RBD protein (anti-spike) antibodies in the absence of prior COVID-19 vaccine.
The group (N=2,464) had a median age 53 years, 35% female sex, 47% Black or African American race, median CD4 count 649 c/mm3, and 97% with HIV VL <400 cp/m. SARS-CoV-2 infection occurred in 318 persons (13%): 58 with clinical diagnosis and 260 with detectable antibodies. Of these PWH, 304 completed symptom questionnaires: 121 (40%) reported symptoms, but 183 (60%) were asymptomatic. PWH with asymptomatic SARS-CoV-2 infection were more likely to be from Low or Middle Income Regions, of Black or African American race, older in age, and with higher ASCVD risk score. Symptomatic COVID was more common with obesity, metabolic syndrome, and low HDL levels. CD4 counts and HIV viral suppression rates were similar among PWH with symptomatic vs. asymptomatic COVID.
Asymptomatic SARS-CoV-2 infection is common among ART-treated PWH globally. We determined that 60% of infections in PWH were asymptomatic. HIV clinicians must remain vigilant about COVID-19 testing among PWH to identify asymptomatic cases.
Metrics
Details
- Title
- Asymptomatic SARS-CoV-2 Infection is Common among ART-treated People with HIV
- Creators
- Edgar T Overton - University of Alabama at BirminghamIsabelle R Weir - Cancer Research And BiostatisticsMarkella V Zanni - Massachusetts General HospitalStephanie Fischinger - Ragon Institute of MGH, MIT and HarvardRodger D MacArthur - Augusta UniversityJudith A Aberg - Icahn School of Medicine at Mount SinaiKathleen V Fitch - Massachusetts General HospitalMichael Frank - Medical College of WisconsinHelmut Albrecht - Palmetto HealthElliot Goodenough - Drexel UniversityFrank S Rhame - Abbott Northwestern HospitalCarl J Fichtenbaum - University of CincinnatiGerald S Bloomfield - Duke UniversityCarlos Malvestutto - The Ohio State University Wexner Medical CenterKhuanchai Supparatpinyo - Chiang Mai UniversitySara McCallum - Massachusetts General HospitalPamela S Douglas - Duke UniversityGalit Alter - Ragon Institute of MGH, MIT and HarvardHeather Ribaudo - Cancer Research And BiostatisticsSteven K Grinspoon - Massachusetts General Hospital
- Publication Details
- Journal of acquired immune deficiency syndromes (1999), v 90(4), pp 377-381
- Publisher
- Lippincott
- Grant note
- U01 HL123339 / NHLBI NIH HHS U01 HL123336 / NHLBI NIH HHS UM1 AI068636 / NIAID NIH HHS UM1 AI106701 / NIAID NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Infectious Diseases (and HIV Medicine)
- Web of Science ID
- WOS:000815533400002
- Scopus ID
- 2-s2.0-85132752311
- Other Identifier
- 991019168604204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases